参考资料:[1] Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline. Retrieved May 2, 2024, from https://www.novartis.com/news/media-releases/novartis-enters-agreement-acquire-mariana-oncology-strengthening-radioligand-therapy-pipeline[2] BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline. Retrieved May 2, 2024, from https://bridgebio.com/news/bridgebio-launches-bridgebio-oncology-therapeutics-bbot-with-200m-of-private-external-capital-to-accelerate-the-development-of-its-novel-precision-oncology-pipeline/[3] Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality. Retrieved May 2, 2024, from https://www.delphiatx.com/news/delphia-therapeutics-launches-to-pioneer-a-new-field-of-cancer-medicines-activation-lethality/[4] Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings. Retrieved May 2, 2024, from https://reunionneuro.com/2024/05/02/reunion-neuroscience-inc-announces-103-million-series-a-financing-co-led-by-mpm-bioimpact-and-novo-holdings/